Glimestar M4 Tablet PR is a combination oral hypoglycemic agent containing Glimepiride 4mg and Metformin 500mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class drug, stimulates pancreatic beta cells to release insulin, thereby reducing blood glucose levels. Metformin, a biguanide, improves insulin sensitivity by decreasing hepatic glucose production and enhancing peripheral glucose uptake and utilization. This dual mechanism addresses both insulin deficiency and insulin resistance, providing effective glycemic control in patients inadequately controlled by diet and exercise alone. Glimestar M4 Tablet PR is typically prescribed when monotherapy with either agent is insufficient or when combination therapy is preferred to optimize therapeutic outcomes. The prolonged-release formulation ensures a gradual release of active ingredients, promoting steady plasma concentrations, reducing dosing frequency, and potentially minimizing gastrointestinal side effects commonly associated with metformin. Patients should adhere to prescribed dosages and maintain regular monitoring of blood glucose levels, renal function, and hepatic parameters during therapy. Common adverse effects may include hypoglycemia, gastrointestinal disturbances, and rare allergic reactions. Glimestar M4 Tablet PR should be used cautiously in patients with renal impairment, hepatic dysfunction, or other contraindications. Consultation with a healthcare professional is essential before initiating or adjusting therapy.